Skip to main content

Table 3 Crude prevalence of antimicrobial use by ward specialty/subclass/hospital type; total results for Global and ECDC-PPS 2017 (Belgium, acute care hospitals)

From: Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

 

Patients with at least one antimicrobial

N

Crude prevalence (%)

95% CI

N

Crude prevalence (%)

95% CI

N

Crude prevalence (%)

95% CI

N

Crude prevalence (%)

95% CI

Ward specialty

Total

Medicine

Surgery

ICU

All patients

7577

27.1

26.5–27.6

4886

24.6

24.0–25.2

1988

29.6

28.5–30.7

703

51.0

48.4–53.7

Adultsa

7095

27.1

26.6–27.7

4461

24.4

23.8–25.1

1966

29.4

28.3–30.5

668

55.1

52.3–57.9

Childrena

430

32.4

29.9–34.9

393

31.6

29.0–34.2

22

47.8

33.4–62.3

15

38.5

23.2–53.7

Neonatesa

52

9.8

7.3–12.3

32

7.9

5.3–10.5

0

  

20

15.8

9.4–22.1

Per antimicrobial subclass

 A07AA

59

0.21

0.16–0.26

52

0.26

0.19–0.33

2

0.03

0.00–0.07

5

0.36

0.05–0.68

 D01BA

6

0.02

0.00–0.04

4

0.02

0.00–0.04

2

0.03

0.00–0.07

0

  

 J01

7323

26.2

25.6–26.7

4664

23.4

22.8–24.0

1973

29.3

28.3–30.4

686

49.8

47.1–52.4

 J02

357

1.27

1.14–1.41

270

1.36

1.20–1.52

36

0.54

0.36–0.71

51

3.70

2.70–4.70

 J04A

79

0.28

0.22–0.34

41

0.21

0.14–0.27

35

0.52

0.35–0.69

3

0.22

0.00–0.46

 J05b

95

0.34

0.27–0.41

87

0.44

0.35–0.53

1

0.01

0.00–0.04

7

0.51

0.13–0.88

 P01AB

149

0.53

0.45–0.62

118

0.59

0.49–0.70

27

0.40

0.25–0.55

4

0.29

0.01–0.57

Per hospital typec

 Primary

4866

27.0

26.3–27.6

3135

24.4

23.6–25.1

1327

30.1

28.7–31.4

404

53.1

49.5–56.6

 Secondary

1768

26.1

25.0–27.1

1143

23.1

21.9–24.3

455

30.7

28.4–33.1

170

48.3

43.1–53.5

 Tertiary

907

29.5

27.9–31.1

583

28.9

26.9–30.9

203

24.8

21.9–27.8

121

51.0

44.7–57.4

  1. CI Confidence interval, ECDC European Centre for Disease Prevention and Control, ICU Intensive care units, N Total number of patients with at least one antimicrobial, PPS Point prevalence survey
  2. A07AA intestinal antiinfectives, D01BA antifungals for systemic use, J01 antibacterials for systemic use, J02 antimycotics for systemic use, J04A drugs for treatment of tuberculosis, J05 antivirals agents, P01AB nitroimidazole-derived antiprotozoals
  3. aThe classification of adults, children and neonates is based on the ward type
  4. bJ05 only included in the Global-PPS
  5. cResults of the specialized hospital (N = 1) not shown